Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16

Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16–Related Cancer

Published:2019-01-01 Issue:1 Volume:5 Page:67
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Massarelli Erminia¹,William William²,Johnson Faye²,Kies Merrill²,Ferrarotto Renata²,Guo Ming³,Feng Lei⁴,Lee J. Jack⁴,Tran Hai²,Kim Young Uk⁵,Haymaker Cara⁶,Bernatchez Chantale⁵,Curran Michael⁷,Zecchini Barrese Tomas⁶,Rodriguez Canales Jaime⁶,Wistuba Ignacio⁶,Li Lerong⁸,Wang Jing⁸,van der Burg Sjoerd H.⁹,Melief Cornelis J.¹⁰¹¹,Glisson Bonnie²

Affiliation:

1. Department of Medical Oncology, City of Hope National Medical Center, Duarte, California

2. Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston

3. Department of Pathology, University of Texas MD Anderson Cancer Center, Houston

4. Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston

5. Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston

6. Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston

7. Department of Immunology, University of Texas MD Anderson Cancer Center, Houston

8. Department of Bioinformatics and Computational Biology, University of Texas MD Anderson Cancer Center, Houston

9. Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands

10. Department of Immunohematology and Blood Tranfusion, Leiden University Medical Center, Leiden, the Netherlands

11. ISA Pharmaceuticals, Leiden, the Netherlands

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Reference31 articles.

1. Intratumoral HPV16-specific T cells constitute a type i-oriented tumor microenvironment to improve survival in HPV16-driven oropharyngeal cancer.;Welters;Clin Cancer Res,2018

2. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.;Seiwert;Lancet Oncol,2016

3. Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE-012 expansion cohort.;Chow;J Clin Oncol,2016

4. Pembrolizumab for platinum- and cetuximab-refractory head and neck cancer: results from a single-arm, phase II study.;Bauml;J Clin Oncol,2017

5. Nivolumab for recurrent squamous-cell carcinoma of the head and neck.;Ferris;N Engl J Med,2016

Cited by 331 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Glioblastoma vaccines: past, present, and opportunities;eBioMedicine;2024-02

2. A phase 1 trial of human telomerase reverse transcriptase (hTERT) vaccination combined with therapeutic strategies to control immune-suppressor mechanisms;Experimental Biology and Medicine;2024-01-31

3. Progress in the treatment of anal cancer: an overview of the latest investigational drugs;Expert Opinion on Investigational Drugs;2024-01-26

4. Unlocking PD‐1 antibody resistance: The MUC1 DNA vaccine augments CD8⁺ T cell infiltration and attenuates tumour suppression;Scandinavian Journal of Immunology;2024-01-19

5. Advances, opportunities and challenges in developing therapeutic cancer vaccines;Critical Reviews in Oncology/Hematology;2024-01